CTOR NASDAQ
Citius Oncology, Inc.
1W: -9.5%
1M: +22.2%
3M: +34.0%
YTD: -12.0%
1Y: -51.8%
$0.95
-0.03 (-3.06%)
Weekly Expected Move ±13.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships18
As Filer
counterparties named
2
As Counterparty
mentioned by others
4
Rel. Types
2022-10-19
Earliest Filing
2025-07-18
Latest Filing
partner: 9
acquirer: 4
investor: 3
target: 2
Counterparties (Filed by CTOR)
18 relationshipsCompanies named in CTOR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Maxim Group LLC | MMS | partner | Placement agent for the public offering of common stock and warrants | 2025-07-18 | View |
| Equiniti Trust Company, LLC | — | partner | Transfer agent and warrant agent for the common stock and warrants | 2025-07-18 | View |
| Dr. Reddy's Laboratories SA | RDY | partner | Original licensor of E7777 to Citius Pharma | 2025-04-03 | View |
| Eisai Co., Ltd. | — | partner | Original licensor of E777 to Dr. Reddy's and current counterparty for milestone payments | 2025-04-03 | View |
| Dr. Reddy's Laboratories SA | RDY | partner | Agreed to partial deferral of milestone payment under Asset Purchase Agreement | 2024-09-13 | View |
| Dr. Reddy's Laboratories, Ltd. | RDY | partner | Parent company of Dr. Reddy's Laboratories SA | 2024-09-13 | View |
| Citius Pharmaceuticals, Inc. | CTXR | partner | Counterparty to the Asset Purchase Agreement | 2024-09-13 | View |
| Citius Oncology, Inc. | CTOR | partner | Counterparty to the Merger Agreement | 2024-04-29 | View |
| Citius Oncology, Inc. | CTOR | partner | Counterparty to the Merger Agreement | 2024-01-18 | View |
| 10XYZ Holdings LP | — | investor | Sponsor holding Parent common stock and rights | 2023-10-24 | View |
| TenX Keane Acquisition | — | acquirer | Parent company entering merger agreement | 2023-10-24 | View |
| Citius Pharmaceuticals, Inc. | CTXR | target | Company entering merger agreement | 2023-10-24 | View |
| Citius Oncology, Inc. | CTOR | target | SpinCo and surviving corporation in merger | 2023-10-24 | View |
| TenX Keane Acquisition | — | acquirer | Issuer of the promissory note | 2023-10-18 | View |
| TenX Keane Acquisition | — | acquirer | Issuer of the promissory note seeking funding for a business combination | 2023-07-18 | View |
| Maxim Group LLC | MMS | acquirer | Underwriter representative for the public offering | 2022-10-19 | View |
| Maxim Partners LLC | — | investor | Purchaser of representative shares | 2022-10-19 | View |
| 10XYZ Holdings LP | — | investor | Sponsor holding founder shares and purchasing private placement units | 2022-10-19 | View |
Mentioned As Counterparty
2 mentionsOther companies that named CTOR in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Shareholder Vote | View | |
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-08-12 | Officer/Director Change; Exhibits | View | |
| 2026-08-05 | Other Events; Exhibits | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-05-15 | Earnings Release; Exhibits | View | |
| 2026-05-06 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-04-29 | Other Events; Exhibits | View | |
| 2026-04-28 | Delisting Notice | View | |
| 2026-03-31 | Other Events; Exhibits | View | |
| 2026-03-10 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-12-01 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-27 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-10-23 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-19 | Unregistered Sales of Equity Securities; Departure/Election of Directors; Appointment of Officers; F | View | |
| 2025-09-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR